Metoclopramide Hydrochloride (Paspertinum) Veterinary Grade API is supplied as a white to off-white crystalline powder intended for further processing into non-sterile solid oral, liquid oral, sterile parenteral, equine oral paste, compounded capsule, and granule/premix dosage forms. The following application routes are separated by unit operation rather than by species label, because the same API particle-size distribution behaves differently in direct-compression, wet-granulation, aseptic-filtration, and fluid-bed drying lines. Compaction behavior of metoclopramide hydrochloride in solid oral dosage forms is governed by its low single-dose mass; a 5 mg tablet with total core mass of 120 mg contains 4.17% w/w API, and a 10 mg tablet with total core mass 160 mg contains 6.25% w/w API, leaving the remainder as diluent and disintegrant. Direct compression is feasible when the API lot particle size D90 ≤ 100 µm and the bulk density is 0.45–0.60 g/mL; where the API fraction falls below 5% w/w, high-shear wet granulation with purified water or 5% w/w povidone K30 solution is preferred because dry blends at this dilution tend to segregate in bin-to-press transfer. The granulation process is performed in a high-shear mixer at impeller speed 200–400 rpm and chopper speed 1500–3000 rpm to endpoint torque 3.5–7.5 Nm; the wet mass is then dried in a fluid-bed dryer at inlet air temperature 55–65°C to residual moisture 1.5–2.5% w/w. Compression is carried out on a rotary tablet press with precompression 4–6 kN and main compression 8–15 kN, target hardness 40–70 N, friability ≤1.0% per Ph. Eur. 2.9.7, and disintegration ≤15 min per Ph. Eur. 2.9.1. Release testing follows Ph. Eur. 5.1.4 for non-sterile microbiological quality, Ph. Eur. 2.9.40 and USP <905> for uniformity of dosage units, VICH GL8 for stability, and VICH GL18 for residual solvents. Granulation fluid pH is maintained below 6.0 because alkalization above 7.0 can deprotonate the hydrochloride and reduce dissolution rate. Finished products are biconvex round scored tablets of 5 mg and 10 mg strength packed in PVC/PVDC/aluminium blisters for companion-animal veterinary markets.

What Governs Filtration and Container Closure Selection for Metoclopramide HCl 5 mg/mL Parenterals?

Sterile parenteral processing of metoclopramide hydrochloride starts from a 5 mg/mL solution, equivalent to 0.5% w/v API, prepared in water for injection at 20–30°C under nitrogen sparging. The formulation includes 0.8% w/v sodium chloride for isotonicity; 1.5% v/v benzyl alcohol is added only in multi-dose formats where regional authorization permits. Single-dose ampoules and vials omit preservatives to comply with Ph. Eur. 5.1.1 and EU GMP Annex 1 requirements for sterile filtration, aseptic assembly, and environmental monitoring. pH is adjusted to 3.0–5.0 using dilute hydrochloric acid or sodium hydroxide; pH above 6.5 is avoided because the ionized hydrochloride converts to the less soluble free base, which can precipitate during temperature excursions in the filling line. The bulk solution is passed through a 0.22 µm sterilizing-grade PVDF or PES filter, with filter integrity testing by bubble point or diffusion, and endotoxin release limit <0.5 EU/mg per Ph. Eur. 2.6.14 unless a stricter regional monograph value applies. Aseptic filling occurs in an ISO 5 unidirectional-airflow zone into Type I glass ampoules or rubber-stoppered vials; container closure integrity is verified according to Ph. Eur. 3.2.1 and USP <1207>. Dissolved oxygen in the bulk solution is controlled below 2.0 mg/L to limit oxidative degradation; line speed is therefore balanced against residence time in stainless steel holding vessels. Published data for terminal steam sterilization of this specific 5 mg/mL formulation is limited, so aseptic filtration rather than autoclaving is the standard manufacturing route. Finished product types are 2 mL, 10 mL, and 20 mL vials or ampoules stored below 25°C and protected from light.

Buffering Capacity, Preservative Partitioning, and Dropper Accuracy in Metoclopramide Oral Liquids

Oral liquid dosage forms for small-animal use are produced at 1 mg/mL and 5 mg/mL metoclopramide hydrochloride, corresponding to 0.1% w/v and 0.5% w/v API, respectively. The aqueous vehicle contains 10–20 mM citrate buffer to hold pH 5.0–5.5; sorbitol solution at 20–40% w/v or glycerin at 10–20% w/v is incorporated to increase palatability and viscosity, while sodium benzoate 0.1% w/v or methylparaben 0.18% w/v plus propylparaben 0.02% w/v is used for microbiological control. Non-sterile release testing follows Ph. Eur. 5.1.4, and stability is assigned under VICH GL8 with light-protected storage. The API is dissolved in purified water in a closed stainless steel vessel with top-mounted agitator at 150–300 rpm; preservatives are dissolved separately in the heated sorbitol/glycerin phase at 45–60°C before mixing. The combined solution is cooled to 20–25°C, adjusted to final weight, and passed through a 10 µm clarifying filter. Filling is performed on automated piston or peristaltic pumps into amber high-density polyethylene or polyethylene terephthalate bottles; dropper accuracy is tested at ±10% of labeled drop mass because drop mass varies with surface tension and container angle. Storage below 25°C and protection from light are required; prolonged contact with low-density polyethylene beyond stability data is avoided due to possible sorbitol container interaction. Finished product types are 15 mL, 30 mL, and 100 mL dropper bottles or multi-dose oral syringes for cats and dogs.

For post-operative ileus adjunct protocols in equine medicine, metoclopramide hydrochloride is compounded as a 0.2%–0.5% w/w non-aqueous oral paste because the API has an aversive bitter taste and because dose titration across 100–600 kg animals is impractical with fixed-dose tablets. The paste vehicle is a mixture of medium-chain triglycerides, polyethylene glycol 400, and polyethylene glycol 3350, with colloidal silicon dioxide 2–5% w/w as suspending agent; the API is levigated with a portion of the liquid carrier before high-shear rotor-stator dispersion at 3000–10,000 rpm. To reduce grittiness and improve content uniformity, the dispersion is passed through a three-roll mill until particle size D90 ≤ 75 µm is confirmed by microscopy. The paste is then deaerated under vacuum and filled into 30 mL or 40 mL calibrated multidose syringes at 25–40°C; cooling to 15–25°C produces a semisolid consistency that prevents settling. Compounding under this configuration follows USP <795> and applicable veterinary pharmacy regulations; if produced as an authorized oral paste dosage form, release testing includes Ph. Eur. 2.9.5 for uniformity of mass and VICH GL8 stability. The polyethylene glycol-based vehicle is hygroscopic, so syringes must be closed with low-moisture-ingress caps and protected from humidity; published data for this specific equine oral paste configuration is limited regarding beyond-use at room temperature, so a conservative dating period is applied. Finished product types are graduated multidose oral paste syringes with 0.5 g, 1 g, and 2 g markings, not a food-producing equine product in regions with withdrawal restrictions.

When Veterinary Compounding Facilities Convert API Powder into Metoclopramide Capsules

Non-sterile compounding of metoclopramide hydrochloride into capsules for companion and exotic animals uses the powder form of the API, with incoming identity confirmed by infrared absorption per Ph. Eur. 2.2.24 and residual solvents reported against VICH GL18. Compounded strengths are typically 2.5 mg, 5 mg, and 10 mg per capsule; the API addition ratio in the total fill mass ranges from 2.5% w/w to 15% w/w depending on capsule shell size and filler system composed of lactose monohydrate, microcrystalline cellulose, or both. The process follows USP <795> and uses geometric dilution in a glass mortar for batch sizes under 100 capsules; larger batches are blended in a low-shear tumble mixer at 10–25 rpm for 15–30 min. Blend homogeneity is evaluated with at least 10 sampling points and acceptance range 90.0%–110.0% of labeled potency before capsule filling. Filling is performed with manual or semiautomatic capsule machines using size 3 or size 4 gelatin or HPMC shells; filled capsules are weight-sorted within ±5% of target fill weight. The API powder in this compounding configuration is not suitable for sustained-release modification because the intended clinical use is immediate-release antiemetic dosing and because altered dissolution would require in vivo bioequivalence data that are typically unavailable in a compounding setting. Beyond-use dates are assigned conservatively at 90–180 days per USP <795> based on moisture and light exposure. Finished product types are unit-dose capsules packaged in light-resistant, tight containers for veterinary prescription use.

Granule and Premix Intermediates That Meet Non-Sterile Pharmacopoeial Limits for Metoclopramide HCl

Metoclopramide hydrochloride granules intended for reconstitution into an oral suspension or for further blending into premix intermediates are produced by fluid-bed top-spray granulation. The active granule formula contains 10 mg/g API (1.0% w/w), pregelatinized starch or povidone K25 binder at 0.8%–1.5% of dry powder mass, and microcrystalline cellulose as filler; a higher-loading premix intermediate may contain 50 mg/g API (5.0% w/w) for repackaging or regional reconstitution. The fluid-bed process uses inlet air temperature 55–65°C, spray rate 5–15 g/min per kg of powder, product temperature 28–35°C, and final residual moisture not exceeding 2.0% w/w. Dried granules are screened through a 0.8–1.0 mm sieve; batch-to-batch particle size and bulk density variation is held within ±5% of target because sachet fill weight uniformity is density-dependent. Non-sterile release testing follows Ph. Eur. 5.1.4, and blend uniformity for premix intermediates is tested using a 10-point sampling plan with acceptance range 90.0%–110.0% of label claim. Reconstitution is typically carried out with purified water to produce a 1 mg/mL oral suspension or solution; the reconstituted product is stored at 2–8°C and used within 14 days unless preservative challenge testing under Ph. Eur. 5.1.3 supports a longer period. Finished product types are 10 mg/g granules in foil-laminate sachets, 50 mg/g premix intermediates in high-barrier containers, and reconstitutable oral suspension kits for in-clinic dosing.